Compare Stocks: ADAP, NK, AUTL, and VYGR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.06 -10.5%	$0.09	$0.04 ▼ $0.36	$15.35M	2.49	57.14 million shs	49.26 million shs
AUTL Autolus Therapeutics	$1.54 -2.8%	$2.00	$1.18 ▼ $2.58	$408.56M	2.15	1.79 million shs	236,711 shs
NK NantKwest	$6.98 +1.7%	$28.01	$2.52 ▼ $45.42	$763.23M	2.61	1.57 million shs	16.54 million shs
VYGR Voyager Therapeutics	$1.77 -5.1%	$2.90	$1.75 ▼ $5.48	$109.38M	1.28	642,205 shs	33,721 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	0.00%	0.00%	0.00%	0.00%	-20.14%
AUTL Autolus Therapeutics	-2.47%	-8.14%	-22.17%	+8.97%	+1.94%
NK NantKwest	0.00%	0.00%	0.00%	0.00%	+186.07%
VYGR Voyager Therapeutics	-7.92%	-9.71%	-40.76%	-40.00%	-61.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.06 -10.5%	$0.09	$0.04 ▼ $0.36	$15.35M	2.49	57.14 million shs	49.26 million shs
AUTL Autolus Therapeutics	$1.54 -2.8%	$2.00	$1.18 ▼ $2.58	$408.56M	2.15	1.79 million shs	236,711 shs
NK NantKwest	$6.98 +1.7%	$28.01	$2.52 ▼ $45.42	$763.23M	2.61	1.57 million shs	16.54 million shs
VYGR Voyager Therapeutics	$1.77 -5.1%	$2.90	$1.75 ▼ $5.48	$109.38M	1.28	642,205 shs	33,721 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	0.00%	0.00%	0.00%	0.00%	-20.14%
AUTL Autolus Therapeutics	-2.47%	-8.14%	-22.17%	+8.97%	+1.94%
NK NantKwest	0.00%	0.00%	0.00%	0.00%	+186.07%
VYGR Voyager Therapeutics	-7.92%	-9.71%	-40.76%	-40.00%	-61.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	0.00	N/A	N/A	N/A
AUTL Autolus Therapeutics	2.86	Moderate Buy	$10.00	532.91% Upside
NK NantKwest	0.00	N/A	N/A	N/A
VYGR Voyager Therapeutics	2.75	Moderate Buy	$16.50	787.10% Upside

Current Analyst Ratings Breakdown

Latest ADAP, NK, AUTL, and VYGR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	VYGR Voyager Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
8/27/2026	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/13/2026	AUTL Autolus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/10/2026	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/3/2026	AUTL Autolus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$10.00
7/31/2026	AUTL Autolus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 10/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$178.03M	0.09	N/A	N/A	$0.05 per share	1.16
AUTL Autolus Therapeutics	$75.39M	5.58	N/A	N/A	$0.67 per share	2.36
NK NantKwest	$40K	19,080.70	N/A	N/A	$1.23 per share	5.67
VYGR Voyager Therapeutics	$40.37M	2.84	N/A	N/A	$3.53 per share	0.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$70.81M	-$0.65	N/A	N/A	N/A	-260.82%	-163.73%	-75.83%	N/A
AUTL Autolus Therapeutics	-$287.53M	-$1.06	N/A	N/A	N/A	-238.66%	-178.66%	-49.34%	10/29/2026 (Estimated)
NK NantKwest	-$65.79M	-$0.70	N/A	N/A	N/A	-76,658.58%	-56.06%	-46.93%	N/A
VYGR Voyager Therapeutics	-$119.72M	-$1.80	N/A	N/A	N/A	-312.63%	-57.92%	-45.00%	11/9/2026 (Estimated)

Latest ADAP, NK, AUTL, and VYGR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	AUTL Autolus Therapeutics	-$0.21	N/A	N/A	N/A	$39.54 million	N/A
11/9/2026	Q3 2026	VYGR Voyager Therapeutics	-$0.41	N/A	N/A	N/A	$6.35 million	N/A
8/11/2026	Q2 2026	AUTL Autolus Therapeutics	-$0.21	-$0.15	+$0.06	-$0.15	$38.56 million	$45.69 million
8/6/2026	Q2 2026	VYGR Voyager Therapeutics	-$0.4838	-$0.40	+$0.0838	-$0.40	$4.52 million	$3.17 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
NK NantKwest	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	N/A	1.52	1.29
AUTL Autolus Therapeutics	1.04	4.89	4.40
NK NantKwest	N/A	4.74	4.74
VYGR Voyager Therapeutics	N/A	7.51	7.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
AUTL Autolus Therapeutics	72.83%
NK NantKwest	9.38%
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.44%
AUTL Autolus Therapeutics	25.70%
NK NantKwest	71.73%
VYGR Voyager Therapeutics	12.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	232.08 million	Optionable
AUTL Autolus Therapeutics	752	266.16 million	197.76 million	Optionable
NK NantKwest	160	109.35 million	N/A	Not Optionable
VYGR Voyager Therapeutics	141	61.62 million	53.79 million	Optionable

ADAP, NK, AUTL, and VYGR Headlines

Recent News About These Companies

Voyager Appoints Robin Swartz As President, CEO Transition Expected In Q1 2027; Stock Down

October 22 at 6:20 PM | rttnews.com

Robin Swartz Appointed President of Voyager Therapeutics with CEO Succession Planned for 2027

October 21 at 7:28 PM | kalkinemedia.comK

Voyager Announces CEO Succession Plan, Appoints Robin Swartz President

October 21 at 8:01 AM | globenewswire.com

Voyager Therapeutics (NASDAQ:VYGR) Stock Breaks Below 50 Day Moving Average - Here's Why

October 21 at 3:39 AM | marketbeat.com

HC Wainwright keeps USD 25 target for Voyager Therapeutics stock

October 20 at 1:36 PM | ad-hoc-news.deA

Voyager Therapeutics (NASDAQ:VYGR) Share Price Breaks Below 50 Day Moving Average - Here's What Happened

October 13, 2026 | marketbeat.com

Voyager Therapeutics stock gets Wells Fargo Buy rating and USD 10 target

October 6, 2026 | ad-hoc-news.deA

Voyager Therapeutics (NASDAQ:VYGR) Shares Break Below Fifty Day Moving Average - Here's What Happened

September 26, 2026 | marketbeat.com

Why Voyager Therapeutics, Inc.’s (VYGR) Stock Is Down 5.05%

September 24, 2026 | aaii.comA

Voyager Therapeutics, Inc. (VYGR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

September 10, 2026 | seekingalpha.com

Voyager to Present at Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

TD Cowen Remains a Buy on Voyager Therapeutics (VYGR)

August 24, 2026 | theglobeandmail.com

Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates

August 6, 2026 | zacks.com

Voyager Reports Second Quarter 2026 Financial and Operating Results

August 6, 2026 | finance.yahoo.com

Voyager Therapeutics: Q2 Earnings Snapshot

August 6, 2026 | khou.comK

Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst

August 4, 2026 | theglobeandmail.com

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

July 13, 2026 | markets.businessinsider.com

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026

July 13, 2026 | globenewswire.com

Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make Money

July 2, 2026 | aol.comA

Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime' to Make Money

July 2, 2026 | 247wallst.com

Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside

June 30, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ADAP, NK, AUTL, and VYGR Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Autolus Therapeutics NASDAQ:AUTL

$1.54 -0.05 (-2.85%)

As of 10:10 AM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

NantKwest NASDAQ:NK

NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.

Voyager Therapeutics NASDAQ:VYGR

$1.76 -0.10 (-5.11%)

As of 10:10 AM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADAP, NK, AUTL, and VYGR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADAP, NK, AUTL, and VYGR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADAP, NK, AUTL, and VYGR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ADAP, NK, AUTL, and VYGR Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

Autolus Therapeutics NASDAQ:AUTL

NantKwest NASDAQ:NK

Voyager Therapeutics NASDAQ:VYGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADAP, NK, AUTL, and VYGR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADAP, NK, AUTL, and VYGR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADAP, NK, AUTL, and VYGR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ADAP, NK, AUTL, and VYGR Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

Autolus Therapeutics NASDAQ:AUTL

NantKwest NASDAQ:NK

Voyager Therapeutics NASDAQ:VYGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools